The initiative aims to secure funding through the Health Program, under the priority focusing on biotechnologies and digital technologies.

The project's approval is contingent upon a shareholder meeting scheduled for late August, where the technical and economic indicators will be presented for endorsement.

Antibiotice has committed to ensuring the financial capacity to cover its own contribution to both eligible and ineligible project expenses.

Furthermore, the company said it would maintain the investment for a period of five years following its completion.

Shares in Antibiotice, majority owned by the Ministry of Healthcare, were up 5.91% to RON 2.60 on Tuesday afternoon trading on the BVB.